Jin Wang

Jin Wang, Ph.D., is a Professor at Baylor College of Medicine, holding the prestigious Michael E. DeBakey, M.D., Professorship in Pharmacology and Biochemistry and Molecular Pharmacology. He also serves as Professor in Molecular and Cellular Biology and as Director of the Center for NextGen Therapeutics. Dr. Wang is a Member of the Dan L Duncan Comprehensive Cancer Center, demonstrating his significant contributions to cancer research.

• BS in Chemistry from Peking University (2003)
• PhD in Organic Chemistry from The Ohio State University (2007)
• Postdoctoral Training in Drug Delivery and Nanomedicine at University of North Carolina at Chapel Hill (2011)

Dr. Wang's research focuses on chemical biology approaches to drug discovery, specializing in targeted protein degradation, small molecule inhibitors, and novel imaging probes. His lab has pioneered the development of RealThiol, the first reversible reaction-based glutathione probe for live-cell imaging, and SI-2 inhibitors targeting the challenging SRC-3 oncoprotein. Current research emphasizes targeted protein degradation strategies, chemoproteomics for covalent inhibitor discovery, and novel therapeutics for cancer and neurodegenerative diseases.

Analysis of Dr. Wang's recent publications reveals a strong emphasis on targeted protein degradation technologies, particularly PROTACs and molecular glues. His work bridges chemical biology and therapeutic development, with significant contributions to cancer immunotherapy through RIPK1 degraders and to Alzheimer's disease through novel epoxide hydrolase inhibitors. The research demonstrates consistent innovation in probe development, drug design, and translational applications.

• Michael E. DeBakey, M.D., Professorship in Pharmacology (2021)
• Teaching Award - Outstanding Lecturer (2020)
• Distinguished Faculty Award from Chinese American Chemistry & Chemical Biology Professors Association (2020)
• CPRIT Scholar in Cancer Research (2011)

Dr. Wang actively mentors graduate students and postdoctoral researchers, with several trainees listed in his lab. His research is supported by multiple NIH R01 grants and CPRIT funding totaling millions of dollars, including projects on RIPK1 degraders for cancer immunotherapy, PROTAC development for B-cell malignancies, and novel Alzheimer's disease therapeutics. His laboratory functions as an integrated academic drug discovery unit with capabilities spanning computational modeling, medicinal chemistry, structural biology, and preclinical testing.

The Wang Lab operates as a highly interdisciplinary research group with multiple specialized teams focusing on fluorescent probe development, covalent inhibitor discovery, and therapeutic development for cancer and neurodegenerative diseases. The lab has distributed its RealThiol glutathione probes to over 50 institutions worldwide, demonstrating significant impact in the redox biology community.